Aktis Oncology, Inc. (AKTS)
Nasdaq: AKTS · Pharmaceutical Preparations · filing with the SEC since 2024
Income statement, as filed
In thousands of US dollars (USD), as filed; per-share figures in US dollars; share counts. The fiscal year ends in December.The Form 10-K filed Mar 30, 2026 for the period ended Dec 31, 2025 is not in EDGAR's company facts yet; its figures print once EDGAR carries them.
| Fiscal quarter | Q3 FY26 | Q2 FY26 | Q1 FY26 |
|---|---|---|---|
| Period ending | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 |
| Report filed | Nov 12, 2026 | Aug 13, 2026 | May 11, 2026 |
| Revenue | 3,905 | 3,384 | 3,227 |
| Research and development | 32,125 | 25,280 | 20,036 |
| General and administrative | 6,527 | 7,003 | 5,897 |
| Total operating expenses | 38,652 | 32,283 | 25,933 |
| Operating income | -34,747 | -28,899 | -22,706 |
| Interest and investment income | 4,822 | 4,765 | 4,384 |
| Other income (expense), net | -14 | -10 | -3 |
| Total non-operating income (expense) | 4,808 | 4,755 | 4,381 |
| Net income including non-controlling interests | · | · | -18,325 |
| Net income | -29,939 | -24,144 | -18,325 |
| Net income to common shareholders | -29,939 | -24,144 | -18,325 |
| Earnings per share, basic | -0.54 | -0.44 | -0.38 |
| Earnings per share, diluted | -0.54 | -0.44 | -0.38 |
| Weighted average shares, basic | 55,649,432 | 55,300,107 | 48,630,038 |
| Weighted average shares, diluted | 55,649,432 | 55,300,107 | 48,630,038 |
As filed with the SEC, each figure from the newest report that carries it, and linked to it. Nothing here is computed.Each quarter is three months. A fourth quarter prints only where the company tagged its three months on their own; the whole year is in the annual view.A dot is a line not tagged for that period. r restated by the company in a later report; b a share figure put on the newest basis or filed in the wrong unit. Hover a figure for its filing and note.
What each line is, and the XBRL concept behind it
Revenue what customers paid for what it sold
us-gaap:RevenuesResearch and development spent on inventing what it sells next
us-gaap:ResearchAndDevelopmentExpenseGeneral and administrative the cost of running the company itself
us-gaap:GeneralAndAdministrativeExpenseTotal operating expenses the running costs together
us-gaap:OperatingExpensesOperating income profit from running the business, before interest and tax
us-gaap:OperatingIncomeLossInterest and investment income what its cash and investments earned
us-gaap:InvestmentIncomeInterestOther income (expense), net gains and costs outside the business
us-gaap:OtherNonoperatingIncomeExpenseTotal non-operating income (expense) everything outside the business, together
us-gaap:NonoperatingIncomeExpenseNet income including non-controlling interests the whole group's profit, minority holders' share included
us-gaap:ProfitLossNet income the profit or loss that belongs to the company's shareholders
us-gaap:NetIncomeLossNet income to common shareholders what is left for common shareholders
us-gaap:NetIncomeLossAvailableToCommonStockholdersBasicEarnings per share, basic net income per share outstanding
us-gaap:EarningsPerShareBasicEarnings per share, diluted net income per share, counting every share that could be issued
us-gaap:EarningsPerShareDilutedWeighted average shares, basic the average count of shares outstanding
us-gaap:WeightedAverageNumberOfSharesOutstandingBasicWeighted average shares, diluted the average count with every share that could be issued
us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding